David Atkins CEO, Congenica S ince its founding in 2014, genomic data analysis, interpreta-tion, and reporting company Congenica has honed its decision support and analysis engine via its partnership with Genomics England and the country’s National Health Service (NHS). With a new partnership with U.S.-based precision medicine leader Sanford CEO David Atkins recently took time to chat with Clinical OMICs views of the genomic medicine landscape. Health and fresh off an equity fi nancing round in late 2020, company Editor in Chief Chris Anderson about the company’s plans and his Chris Anderson, Editor in Chief, Clinical OMICs: Can you bring us up to speed on the most signifi cant developments for Congenica over the past fi ve years or so? David Atkins, CEO, Congenica: The big defi ning event for England—that was our fi rst major commercial success and is us was being selected as the exclusive partner for Genomics ongoing. Genomics England was a subsidiary of the NHS that was set up to develop the infrastructure for genomic medicine. as a routine rare disease diagnostic for all patients in England. The offi cial announcement for that go-live will hap-pen over the next few months. Like so many things, that got delayed by the pandemic but is all moving forward now. What we continue to learn is build-We are handing [our platform] over to the NHS who will run it ing a system for application in the real world—to be able to apply whole-ge-nome based diagnosis—is a complex challenge. The benefi t Congenica 40 Clinical OMICs May/June 2021 www.clinicalomics.com